Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for neuroendocrine tumor detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer that binds to a tumor specific protein called somatostatin receptor 2 (SSTR2) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours

NCT Number	NCT07284589
Lead Sponsor	Akiva Mintz
Conditions	Healthy (Controls), Healthy Volunteers, Neuroendocrine (NE) Tumors
Enrollment	200 participants
Start Date	2025-12-11
Primary Completion	2030-04-30 (estimated)
Study Completion	2030-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-08